/
ATOS
$1.98+$0.10 (+5.32%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$18.8M
10M shares
52-week range
$1.70 – $19.35
2% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.89%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-94.02
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $44.2K | $52.8K | $46.6K | $23.0K | $8.0K | $23.0K | $17.0K | $0 |
| Gross profit | −$44.2K | −$52.8K | −$46.6K | −$23.0K | −$8.0K | −$23.0K | −$17.0K | $0 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $4.2M | $7.1M | $6.6M | $9.2M | $15.1M | $17.3M | $14.1M | $21.2M |
| Operating income | −$11.4M | −$17.3M | −$14.6M | −$20.5M | −$27.7M | −$31.4M | −$27.6M | −$37.1M |
| EBITDA | −$11.4M | −$17.2M | −$14.6M | −$20.6M | −$27.0M | −$30.1M | −$25.5M | −$34.8M |
| Net income | −$11.4M | −$17.2M | −$17.8M | −$20.6M | −$27.0M | −$30.1M | −$25.5M | −$34.8M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -82.50 | -30.45 | -29.55 | -2.70 | -3.15 | -3.60 | -3.00 | -4.04 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $54M | $-4.33 | $-4.43–$-4.22 | 2 |
| 2027 | $82M | $-3.46 | $-3.80–$-3.12 | 2 |
| 2028 | $119M | $2.59 | $-3.00–$8.18 | 2 |
| 2029 | $337M | $12.52 | $12.52–$12.52 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$4.34
Price
$1.98
Implied upside
+119%
Peer comparison
Atossa Therapeutics, Inc. Common Stock
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
www.atossatherapeutics.com- Employees
- 14
- IPO / List date
- Nov 8, 2012
- HQ
- SEATTLE, WA
Held by traders on TradeandTell
No one on the platform currently holds ATOS.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 109,007 | $573.4K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-02-02 | 1-for-15reverse |
| 2018-04-20 | 1-for-12reverse |
| 2016-08-26 | 1-for-15reverse |
Recent trades on TradeandTell
No one on the platform has traded ATOS yet.
